Cancer – PNOC-013: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Condition or Therapy:
Cancers and tumors, relapsed solid tumor, CNS tumor, refractory solid tumor, CNS tumor, diffuse intrinsic pontine glioma, high-grade glioma, REGN2810 therapy, radiation therapy
Category:
Cancer and Blood Disorders
Study Number: PNOC-013
What is the goal of this study?
The goal of this study is to determine the rate of dose-limiting toxicities, PK of REGN2810 estimated observed terminal half-life, and anti-tumor activity of REGN2810/radiation combination.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 18 years old or younger (phase 1)
- Are between ages 3 to 25 (phase 2)
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Sarah Leary
Research Center: Center for Clinical and Translational Research